Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14751 - 14775 of 15354 in total
Dipraglurant has been used in trials studying the treatment of Parkinson's Disease. It is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).
Investigational
Diminazene, also known as Diminazine, 4,4'-(Diazoamino)benzamidine, 4,4'-(1-triazene-1,3-diyl)bis-benzenecarboximidamide, diminazine aceturate, or Diminazene aceturate, is a trypanocidal agent. Major brands of Diminazene are Berenil, Pirocide, Ganasag, and Azidin. This substance is a solid. This compound belongs to the phenylhydrazines. These are compounds containing a phenylhydrazide moiety, which consists of a hydrazide substituent...
Experimental
Matched Description: … Major brands of Diminazene are Berenil, Pirocide, Ganasag, and Azidin. This substance is a solid. ... HTH-type transcriptional regulator QacR, trypsin-1, amiloride-sensitive amine oxidase [copper-containing], and
RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
Investigational
Matched Description: … neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and
IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform
Investigational
Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.
Investigational
CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
Investigational
Matched Description: … dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and
Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity . It is currently in clinical trials for the treatment of a wide range of tumors.
Investigational
Matched Description: … Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity …
Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).
Investigational
Matched Description: … investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and
ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C).
Investigational
Matched Description: … clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and
Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML).
Investigational
Matched Description: … antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and
Phelemin (PHE-MIP) is a methacrylic acid-based copolymer purified to bind to L-phenylalanine and L-phenylalanine-containing peptides. It is under investigation for the treatment of hyperphenylalaninemia.
Investigational
Matched Description: … Phelemin (PHE-MIP) is a methacrylic acid-based copolymer purified to bind to L-phenylalanine and L-phenylalanine-containing …
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment. DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Matched Description: … suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and ... CD-10* or TOP** peptidases, such as prostate cancer, colorectal cancer, melanoma, pancreatic cancer and
OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.
Investigational
OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
Investigational
Investigational
SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and
Clinafloxacin is a fluoroquinolone antibacterial currently under research. It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Investigational
Matched Description: … However, its approval and release have been halted due to the presence of serious side effects. …
Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery).
Investigational
Matched Iupac: … amino-1-[(2S)-2-{[(1S)-1-carbamoyl-2-methylpropyl]carbamoyl}pyrrolidin-1-yl]-1-oxohexan-2-yl]carbamoyl}methyl
Matched Description: … Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple …
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
Matched Description: … AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to …
PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia. Little information has been released about PS386113.
Investigational
Matched Description: … It is being developed by Schering-Plough and Pharmacopeia. …
Displaying drugs 14751 - 14775 of 15354 in total